Nitric Oxide/Cyclic GMP-Dependent Calcium Signalling Mediates IL-6- and TNF-α-Induced Expression of Glial Fibrillary Acid Protein

J Mol Neurosci. 2021 Apr;71(4):854-866. doi: 10.1007/s12031-020-01708-3. Epub 2020 Sep 22.

Abstract

Astrocyte activation is characterized by hypertrophy with increased glial fibrillary acidic protein (GFAP), whose expression may involve pro-inflammatory cytokines. In this study, the effects of pro-inflammatory IL-6 and TNF-α and anti-inflammatory cytokines IL-4 and IL-10 on nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) signalling, intracellular calcium concentration ([Ca2+]i) and GFAP expression were investigated. In human glioblastoma astrocytoma U-373 MG cells, IL-6 and TNF-α, but not IL-4 or IL-10, increased iNOS, cGMP, [Ca2+]i and GFAP expression. The inhibitors of iNOS (1400 W), soluble guanylyl cyclase (ODQ) and IP3 receptors (ryanodine and 2-APB) reversed the increase in cGMP or [Ca2+]i, respectively, and prevented GFAP expression. In rat striatal slices, IL-6 and TNF-α, at variance with IL-4 and IL-10, promoted a concentration-dependent increase in Ca2+ efflux, an effect prevented by 1400 W, ODQ and RY/2APB. These data were confirmed by in vivo studies, where IL-6, TNF-α or the NO donor DETA/NO injected in the striatum of anaesthetised rats increased cGMP levels and increased GFAP expression. The present findings point to NO/cGMP-dependent calcium signalling as part of the mechanism mediating IL-6- and TNF-α-induced GFAP expression. As this process plays a fundamental role in driving neurotoxicity, targeting NO/cGMP-dependent calcium signalling may constitute a new approach for therapeutic interventions in neurological disorders.

Keywords: Astrogliosis; GFAP; NO/cGMP/Ca2+ signalling; Neuroinflammation; Neurological disorders; Pro-inflammatory cytokines.

MeSH terms

  • Animals
  • Astrocytes / drug effects
  • Astrocytes / metabolism
  • Boron Compounds / pharmacology
  • Calcium Channel Blockers / pharmacology
  • Calcium Signaling*
  • Cell Line, Tumor
  • Corpus Striatum / cytology
  • Corpus Striatum / metabolism
  • Cyclic GMP / metabolism
  • Enzyme Inhibitors / pharmacology
  • Glial Fibrillary Acidic Protein / genetics
  • Glial Fibrillary Acidic Protein / metabolism*
  • Humans
  • Imines / pharmacology
  • Interleukin-6 / metabolism*
  • Male
  • Nitric Oxide / metabolism*
  • Oxadiazoles / pharmacology
  • Quinoxalines / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Ryanodine / pharmacology
  • Tumor Necrosis Factor-alpha / metabolism*

Substances

  • 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one
  • 2-aminoethyl diphenylborinate
  • Boron Compounds
  • Calcium Channel Blockers
  • Enzyme Inhibitors
  • Glial Fibrillary Acidic Protein
  • Imines
  • Interleukin-6
  • N-((3-(aminomethyl)phenyl)methyl)ethanimidamide
  • Oxadiazoles
  • Quinoxalines
  • Tumor Necrosis Factor-alpha
  • Ryanodine
  • Nitric Oxide
  • Cyclic GMP